Date: 2016-11-01
Type of information: Results
phase: preclinical
Announcement: results
Company: Neurovive Pharmaceutical (Sweden)
Product: NVP018
Action
mechanism: cyclophilin inhibitor. NVP018 is a potent non-immunosuppressive cyclophilin inhibitor within NeuroVive’s new compound class sangamides. In this cyclophilin inhibitor chemical family, NVP018 is the oral version of its lead compound (NV556) which has undergone extensive preclinical development.
Disease: NASH (non-alcoholic steatohepatitis)
Therapeutic area: Liver diseases - Hepatic diseases
Country:
Trial details:
Latest
news: * On November 1, 2016, NeuroVive Pharmaceutical announced positive pre-clinical results with one of its cyclophilin inhibitors, NVP018, in an experimental model of NASH (non-alcoholic steatohepatitis). The present data shows that NVP018 prevents fibrosis development in a well-validated experimental model of NASH. Further experimental activities with NVP018 within NASH are ongoing. The NASH project is in line with the company’s updated business strategy which includes increased and accelerated efforts in moving high potential discovery projects forward with the aim of out-licensing them in the preclinical phase. Neurovive has implemented a business model going forward that contains two parts. One part involves high potential large indication projects like NASH, for out-licensing in the preclinical phase. The second part is to take drugs for rare diseases with high unmet medical need through clinical development and into the market. NeuroVive’s core research and development area continues to be mitochondrial medicine, with the aim to offer new treatment options to patients with unmet medical needs. There is a continuous growing understanding for the importance of mitochondrial function in many diseases.
In addition, NeuroVive is developing a new class of compounds with a different mode of action that may offer complementary treatment of NASH. This discovery project is based on NeuroVive’s core competence in mitochondrial energy regulation and the partner company Isomerase’s innovative chemistry capabilities.
“The current experimental result in NASH is an excellent example of the strength of the research within NeuroVive and the successful collaboration with Isomerase. The result at hand is an important step forward in our continued development for out-licensing in this therapeutic area”, said Erik Kinnman, CEO NeuroVive.
